Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A9 | P48067 | 20/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 1/20 | 1.00 |
| ▸ | MAPT | P10636 | 1/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 1/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 1/20 | 1.00 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1052569 | 1.00 | SLC6A9 (1.00) | SLC6A9ALDH1A1CYP2D6MAPTCYP2C9 | |
| Hydrochloric Acid SCHEMBL375237 | 0.99 | SLC6A9 (1.00) | SLC6A9ALDH1A1CYP2D6MAPTCYP2C9 | |
| SCHEMBL26840802 | 0.92 | SLC6A9 (0.85) | SLC6A9ALDH1A1CYP2D6MAPTCYP2C9 | |
| SCHEMBL26840804 | 0.92 | SLC6A9 (0.85) | SLC6A9ALDH1A1CYP2D6MAPTCYP2C9 | |
| SCHEMBL6823016 | 0.89 | SLC6A9 (0.80) | SLC6A9ALDH1A1CYP2D6MAPTCYP2C9 | |
| SCHEMBL6826926 | 0.88 | SLC6A9 (0.82) | SLC6A9ALDH1A1CYP2D6MAPTCYP2C9 | |
| SCHEMBL6567625 | 0.87 | SLC6A9 (0.77) | SLC6A9ALDH1A1CYP2D6MAPTCYP2C9 | |
| SCHEMBL6826140 | 0.86 | SLC6A9 (0.75) | SLC6A9ALDH1A1CYP2D6MAPTCYP2C9 | |
| SCHEMBL6565594 | 0.84 | SLC6A9 (0.73) | SLC6A9ALDH1A1CYP2D6MAPTCYP2C9 | |
| SCHEMBL7214281 | 0.84 | SLC6A9 (0.73) | SLC6A9ALDH1A1CYP2D6MAPTCYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 473 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12388726-B2 | Synchronized wireless network slicing | T-MOBILE INNOVATIONS LLC (US) | 2025-08-12 | — | — | US | claimed |
| CN-120146644-A | Two-dimensional irregular leather layout method with defects and computer readable storage medium | 杭州电子科技大学 | 2025-06-13 | — | — | CN | claimed |
| CN-114449606-B | Forwarding path method of reliable virtual network | 武汉船舶通信研究所（中国船舶重工集团公司第七二二研究所） | 2025-06-13 | — | — | CN | claimed |
| US-20250175399-A1 | SYNCHRONIZED WIRELESS NETWORK SLICING | T-MOBILE INNOVATIONS LLC | 2025-05-29 | — | — | US | claimed |
| EP-4561002-A1 | SYNCHRONIZED WIRELESS NETWORK SLICING | T-Mobile Innovations LLC (US) | 2025-05-28 | — | — | EP | claimed |
| CN-119993360-A | Use of chronic inflammation complex index or 3C score in prognosis prediction system for patients with stage II-III colorectal cancer | 南昌大学第二附属医院 | 2025-05-13 | — | — | CN | claimed |
| CN-119574036-A | Water surface aircraft cabin section water-in test device and test method | 中国特种飞行器研究所 | 2025-03-07 | — | — | CN | claimed |
| CN-119397478-A | Fault diagnosis system and method for autonomous berthing-off close-range target and obstacle sensing system | 江苏科技大学 | 2025-02-07 | — | — | CN | claimed |
| CN-118378740-B | Method, system, equipment and medium for calculating automatic falling position of manual jacking | 上海方菱计算机软件有限公司 | 2024-11-22 | — | — | CN | claimed |
| EP-4416954-A1 | 5GC SERVICE BASED ARCHITECTURE OPTIMIZATION OF INITIAL SELECTION IN ROAMING | Telefonaktiebolaget LM Ericsson (publ) (SE) | 2024-08-21 | — | — | EP | claimed |
| CN-114449606-A | Forwarding path method of reliable virtual network | 武汉船舶通信研究所（中国船舶重工集团公司第七二二研究所） | 2022-05-06 | — | — | CN | claimed |
| CN-113971690-A | End-to-end three-dimensional point cloud registration method based on deep learning | 燕山大学 | 2022-01-25 | — | — | CN | claimed |
| US-9504665-B2 | High-dose glycine as a treatment for obsessive-compulsive disorder and obsessive-compulsive spectrum disorders | CLEVELAND W LOUIS (US) | 2016-11-29 | — | — | US | claimed |
| US-9415030-B2 | High-dose glycine as a treatment for obsessive-compulsive disorder and obsessive-compulsive spectrum disorders | CLEVELAND W LOUIS (US) | 2016-08-16 | — | — | US | claimed |
| US-8604080-B2 | High dose glycine as a treatment for obsessive-compulsive disorder and obsessive compulsive spectrum disorders | CLEVELAND W LOUIS (US) | 2013-12-10 | — | — | US | claimed |
| US-20130251635-A1 | HIGH-DOSE GLYCINE AS A TREATMENT FOR OBSESSIVE-COMPULSIVE DISORDER AND OBSESSIVE-COMPULSIVE SPECTRUM DISORDERS | CLEVELAND W LOUIS (US) | 2013-09-26 | — | — | US | claimed |
| US-20100113598-A1 | HIGH DOSE GLYCINE AS A TREATMENT FOR OBSESSIVE-COMPULSIVE DISORDER AND OBSESSIVE COMPULSIVE SPECTRUM DISORDERS | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF (US) | 2010-05-06 | — | — | US | claimed |
| US-7670838-B2 | Coupling of excitation and neurogenesis in neural stem/progenitor cells | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2010-03-02 | — | — | US | claimed |
| WO-2009018368-A1 | COMBINATION TREATMENT OF NMDA (N-METHYL-D-ASPARTATE)-ENHANCER, GLYCINE TRANSPORTER INHIBITOR, D-AMINO ACID OXIDASE INHIBITOR (DAAOI) FOR NEUROPSYCHIATRIC DISORDERS | LOS ANGELES BIOMEDICAL RESEARCH INSTITUTE AT HARBOR-UCLA MEDICAL CENTER (US) | 2009-02-05 | — | — | WO | claimed |
| WO-2008100727-A2 | HIGH-DOSE GLYCINE AS A TREATMENT FOR OBSESSIVE-COMPULSIVE DISORDER AND OBSESSIVE-COMPULSIVE SPECTRUM DISORDERS | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2008-08-21 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130251635-A1 | HIGH-DOSE GLYCINE AS A TREATMENT FOR OBSESSIVE-COMPULSIVE DISORDER AND OBSESSIVE-COMPULSIVE SPECTRUM DISORDERS | SLC1A2, GRIN2D, SLC7A11 | SLC6A9 34/4885ALDH1A1 1140/4885CYP2D6 594/4885 |
| US-20100113598-A1 | HIGH DOSE GLYCINE AS A TREATMENT FOR OBSESSIVE-COMPULSIVE DISORDER AND OBSESSIVE COMPULSIVE SPECTRUM DISORDERS | SLC1A2, GRIN2D, SLC7A11 | SLC6A9 39/4885ALDH1A1 1592/4885CYP2D6 652/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.